Items Tagged ‘stage III’

October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

By

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy


September 15th, 2015

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to Xalkori™ (crizotinib).  Alectinib was previously granted Breakthrough Therapy Designation by the FDA for people with ALK-positive […]

View full entry

Tags: alectinib, ALK inhibitor, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


September 10th, 2015

Updated Trial Results Demonstrating Benefit of Opdivo® Were Released Today at the 16th World Conference on Lung Cancer

By

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference on Lung Cancer (Abstract #736), and the studies showed sustained survival benefit. Both trials showed an estimated 18-month overall survival (OS) rate of 27% (CheckMate […]

View full entry

Tags: CheckMate, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, stage III, stage IV


March 31st, 2015

Chemotherapy after Surgery Appears to Improve Survival in Advanced Bladder Cancer

By

Patients with advanced bladder cancer who receive chemotherapy after surgery to remove the bladder have better overall survival than patients who undergo surgery alone. These findings were presented at the 2015 Genitourinary Cancers Symposium on February 26–28 in Orlando, Florida. Patients with Stage III, or advanced, bladder cancer have cancer that invades through the connective […]

View full entry

Tags: adjuvant chemotherapy, advanced, Bladder Cancer, genitourinary cancer, News, stage III, Stage III Bladder Cancer